StockTipsArenaBeta

BUY Aurobindo Pharma — Goldman Sachs

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byGoldman SachsHorizon: NA (inferred 1 year)7 Aug 2026via CNBC Awaaz.

Entry₹1,580.1Inferred
Target₹1,750
Total upside +10.75%
Stop lossNot given
CMP₹1,589.5Just now
Active+0.59%+10.10%upside left 10 mo left
Follow Goldman Sachs for new calls(100% target hit, 30 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 10 other Long-term calls on AUROPHARMASee 198 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 11:41 am IST
53 supporting18 neutral7 opposing
Supports the BUY call (53)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·21 Oct · yesterday

4 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·7 Oct · 2w ago

Aurobindo Pharma Shares in Focus After USFDA Approval for Perampanel

NewsGoogle News·5 Oct · 2w ago

(opens in new tab)

Aurobindo Pharma USFDA Approval Sparks Rally to New 52-Week High

NewsGoogle News·5 Oct · 2w ago

(opens in new tab)

Aurobindo Pharma rises on getting USFDA`s final nod to manufacture, market Perampanel tablets

NewsGoogle News·5 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (18)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3d ago

(opens in new tab)

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · 2w ago

(opens in new tab)

Aurobindo Pharma Ltd has announced the acquisition of a step-down subsidiary located in the USA.

BSE · Company Update·2 Oct · 3w ago

(opens in new tab)
Weighs against the BUY call (7)

2 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·6 Aug · 3mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Goldman Sachs

Every call and its outcome